A New Generation of Drug Therapies Requires New Business Strategies
Harvard Business
FEBRUARY 27, 2024
The shift to advanced therapeutic modalities (ATMs) promises to change the nature of competition in the pharmaceuticals industry. They are shifting the nature of drug R&D risk and establishing manufacturing as a critical strategic priority alongside therapeutic safety and efficacy while also introducing new commercialization challenges.
Let's personalize your content